On March 31, 2025, the Board of Directors of Sudarshan Pharma Industries Limited held a meeting where important decisions regarding the company's leadership were made. The Board addressed changes that were initially proposed in their meeting held on March 6, 2025, and provided updates on the changes to key positions.

1. Rescinding Appointment of Mr. Manoj Lodha: During the meeting, the Board rescinded its previous decision to appoint Mr. Manoj Lodha as the Executive Director and Chief Financial Officer (CFO) of Sudarshan Pharma Industries Limited. This change comes after Mr. Lodha informed the Board via email on March 29, 2025, that he would not be able to accept the position due to unforeseen circumstances. Consequently, Mr. Lodha's appointment stands canceled, and there are no changes in the Board’s composition.

2. Reinstatement of Mr. Sachin Mehta as Joint Managing Director & CFO: In another key decision, the Board accepted Mr. Sachin Mehta’s withdrawal of his resignation as CFO. Mr. Mehta had initially tendered his resignation on March 6, 2025, which led the Board to consider re-designating him as Joint Managing Director. However, on March 29, 2025, Mr. Mehta communicated his intention to continue in his role as Joint Managing Director and CFO. Upon receiving this communication, the Board decided to reinstate Mr. Mehta in his current roles. The decision ensures that there is no disruption in leadership at Sudarshan Pharma, as Mr. Mehta brings over 18 years of experience in the chemical industry and is well-versed in exports and imports management.

The company noted that these decisions are made in light of the company's ongoing commitment to strong corporate governance practices. There are no changes to the overall structure of the Board, and the company continues to function as before.

3. Details on the Decision Process: The decisions were made following internal discussions and recommendations from the Nomination & Remuneration Committee of the Board. The Board expressed confidence in Mr. Mehta's ability to lead the company in his role and affirmed that there are no new additions or removals from the Board at this time.

The company's leadership changes were formally communicated to both BSE and the relevant regulatory authorities, including SEBI, to ensure compliance with Listing Obligations and Disclosure Requirements. The company’s commitment to transparent governance practices remains strong.

This restructuring within Sudarshan Pharma Industries reflects its focus on stabilizing leadership while navigating unforeseen changes. As the company continues to operate under these updated terms, there is a clear emphasis on maintaining strategic direction and growth.

The Current active IPO are Infonative Solutions Limited,Spinaroo Commercial Limited,Retaggio Industries Limited.

The Closed IPOs are  Identixweb Limited, ATC Energies System Limited, Shri Ahimsa Naturals Limited.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.